{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:06:05Z","timestamp":1793325965666,"version":"4.5.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009042","name":"Universidad de Sevilla","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009042","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of Review<\/jats:title>\n            <jats:p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating inflammatory condition that significantly impacts quality of life. Despite treatment advances, recurrence is common, prompting the exploration of novel therapies such as monoclonal antibodies targeting the type 2 immune response, notably dupilumab. This research aims to evaluate the real-world evidence (RWE) of dupilumab in treating severe CRSwNP, comparing sinonasal outcomes to those observed in randomized clinical trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent Findings<\/jats:title>\n            <jats:p>Significant improvements were noted, with the average SNOT-22 score reduction being 37.2 points post-dupilumab treatment. The nasal polyp size (NPS) showed an average decrease of 3.6 points. The analysis highlighted the practical effectiveness of dupilumab, emphasizing its benefit over conventional therapies in reducing NPS and improving nasal symptoms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The findings advocate for the integration of dupilumab into standard treatment protocols for severe CRSwNP, providing a robust alternative that could potentially reduce the high recurrence rates associated with current management strategies. This study underscores the utility of RWE in assessing the effectiveness of new medical treatments, suggesting that dupilumab offers substantial real-world benefits for patients suffering from this challenging condition.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11882-025-01192-y","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T06:58:21Z","timestamp":1738738701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis"],"prefix":"10.1007","volume":"25","author":[{"given":"Miguel","family":"Rodriguez-Iglesias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Calvo-Henr\u00edquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Martin-Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Garc\u00eda-Lliber\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Maza-Solano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Moreno-Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Izquierdo-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Mart\u00ednez-Capoccioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isam","family":"Alobid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"1192_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","volume":"147","author":"C Bachert","year":"2021","unstructured":"Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol. 2021;147:29\u201336. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.013.","journal-title":"J Allergy Clin Immunol"},{"key":"1192_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0091-6749(77)90171-3","volume":"59","author":"GA Settipane","year":"1977","unstructured":"Settipane GA, Chafee FH. Nasal polyps in asthma and rhinitis. A review of 6,037 patients. J Allergy Clin Immunol. 1977;59:17\u201321. https:\/\/doi.org\/10.1016\/0091-6749(77)90171-3.","journal-title":"J Allergy Clin Immunol"},{"key":"1192_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/ije\/28.4.717","volume":"28","author":"J Hedman","year":"1999","unstructured":"Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol. 1999;28:717\u201322. https:\/\/doi.org\/10.1093\/ije\/28.4.717.","journal-title":"Int J Epidemiol"},{"key":"1192_CR4","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4193\/Rhin21.364","volume":"0","author":"I Sanchez-Collado","year":"2022","unstructured":"Sanchez-Collado I, Mora T, Munoz-Cano R, et al. Prevalence of chronic rhinosinusitis with nasal polyps in Catalonia (Spain): a retrospective, large-scale population-based study. Rhin. 2022;0:0\u20130. https:\/\/doi.org\/10.4193\/Rhin21.364.","journal-title":"Rhin"},{"key":"1192_CR5","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4193\/Rhin23.341","volume":"0","author":"J Mullol","year":"2024","unstructured":"Mullol J, Sastre J, Dom\u00ednguez-Ortega J, et al. Prevalence of chronic rhinosinusitis without\/with nasal polyps according to severity in Spain. Rhin. 2024;0:0\u20130. https:\/\/doi.org\/10.4193\/Rhin23.341.","journal-title":"Rhin"},{"key":"1192_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S0194-59989570152-4","volume":"113","author":"RE Gliklich","year":"1995","unstructured":"Gliklich RE, Metson R. The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg. 1995;113:104\u20139. https:\/\/doi.org\/10.1016\/S0194-59989570152-4.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"1192_CR7","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1398-9995.2005.00725.x","volume":"60","author":"I Alobid","year":"2005","unstructured":"Alobid I, Ben\u00edtez P, Bernal-Sprekelsen M, et al. Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. Allergy. 2005;60:452\u20138. https:\/\/doi.org\/10.1111\/j.1398-9995.2005.00725.x.","journal-title":"Allergy"},{"key":"1192_CR8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.4193\/Rhino11.101","volume":"49","author":"P Sahlstrand-Johnson","year":"2011","unstructured":"Sahlstrand-Johnson P, Ohlsson B, Von Buchwald C, et al. A multi-centre study on quality of life and absenteeism in patients with CRS referred for endoscopic surgery. Rhinology. 2011;49:420\u20138. https:\/\/doi.org\/10.4193\/Rhino11.101.","journal-title":"Rhinology"},{"key":"1192_CR9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/lary.26391","volume":"127","author":"AS DeConde","year":"2017","unstructured":"DeConde AS, Mace JC, Levy JM, et al. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127:550\u20135. https:\/\/doi.org\/10.1002\/lary.26391.","journal-title":"Laryngoscope"},{"key":"1192_CR10","doi-asserted-by":"publisher","first-page":"102286","DOI":"10.1016\/j.amjoto.2019.102286","volume":"41","author":"D Rosati","year":"2020","unstructured":"Rosati D, Rosato C, Pagliuca G, et al. Predictive markers of long-term recurrence in chronic rhinosinusitis with nasal polyps. Am J Otolaryngol. 2020;41. https:\/\/doi.org\/10.1016\/j.amjoto.2019.102286.","journal-title":"Am J Otolaryngol"},{"key":"1192_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4193\/Rhin21.148","volume":"60","author":"C Arancibia","year":"2022","unstructured":"Arancibia C, Langdon C, Mullol J, Alobid I. Twelve-year long-term postoperative outcomes in patients with chronic rhinosinusitis with nasal polyps. Rhinology. 2022;60:261\u20139. https:\/\/doi.org\/10.4193\/Rhin21.148.","journal-title":"Rhinology"},{"key":"1192_CR12","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","volume":"137","author":"P Tomassen","year":"2016","unstructured":"Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137:1449\u2013e14564. https:\/\/doi.org\/10.1016\/j.jaci.2015.12.1324.","journal-title":"J Allergy Clin Immunol"},{"key":"1192_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2500\/ajra.2013.27.3981","volume":"27","author":"MR Chaaban","year":"2013","unstructured":"Chaaban MR, Walsh EM, Woodworth BA. Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy. 2013;27:473\u20138. https:\/\/doi.org\/10.2500\/ajra.2013.27.3981.","journal-title":"Am J Rhinol Allergy"},{"key":"1192_CR14","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jaci.2018.03.004","volume":"141","author":"C Bachert","year":"2018","unstructured":"Bachert C, Zhang N, Hellings PW, Bousquet J. Endotype-driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141:1543\u201351. https:\/\/doi.org\/10.1016\/j.jaci.2018.03.004.","journal-title":"J Allergy Clin Immunol"},{"key":"1192_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","volume":"77","author":"M Shirley","year":"2017","unstructured":"Shirley M. Dupilumab: first global approval. Drugs. 2017;77:1115\u201321. https:\/\/doi.org\/10.1007\/s40265-017-0768-3.","journal-title":"Drugs"},{"key":"1192_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000519228","volume":"183","author":"Q Wu","year":"2022","unstructured":"Wu Q, Zhang Y, Kong W, et al. Which is the best biologic for nasal polyps: dupilumab, omalizumab, or Mepolizumab? A network meta-analysis. Int Arch Allergy Immunol. 2022;183:279\u201388. https:\/\/doi.org\/10.1159\/000519228.","journal-title":"Int Arch Allergy Immunol"},{"key":"1192_CR17","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/all.15205","volume":"77","author":"JL Boechat","year":"2022","unstructured":"Boechat JL, Silva D, Sousa-Pinto B, Delgado L. Comparing biologicals for severe chronic rhinosinusitis with nasal polyps: a network meta-analysis. Allergy Eur J Allergy Clin Immunol. 2022;77:1299\u2013306. https:\/\/doi.org\/10.1111\/all.15205.","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"1192_CR18","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","volume":"149","author":"P Oykhman","year":"2022","unstructured":"Oykhman P, Paramo FA, Bousquet J, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. J Allergy Clin Immunol. 2022;149:1286\u201395. https:\/\/doi.org\/10.1016\/j.jaci.2021.09.009.","journal-title":"J Allergy Clin Immunol"},{"key":"1192_CR19","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence \u2014 what is it and what can it tell us? N Engl J Med. 2016;375:2293\u20137. https:\/\/doi.org\/10.1056\/NEJMsb1609216.","journal-title":"N Engl J Med"},{"key":"1192_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58:1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600.","journal-title":"Rhinology"},{"key":"1192_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.18176\/jiaci.0910","volume":"33","author":"I Alobid","year":"2023","unstructured":"Alobid I, Col\u00e1s C, Castillo J, et al. Spanish consensus on the management of chronic rhinosinusitis with nasal polyps (POLIposis NAsal\/POLINA 2.0). J Investig Allergol Clin Immunol. 2023;33:317\u201331. https:\/\/doi.org\/10.18176\/jiaci.0910.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1192_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","volume":"61","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens WJ, Viskens A-S, Backer V, et al. EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology. 2023;61:194\u2013202. https:\/\/doi.org\/10.4193\/Rhin22.489.","journal-title":"Rhinology"},{"key":"1192_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/all.12715","volume":"70","author":"C Bachert","year":"2015","unstructured":"Bachert C, Mannent L, Naclerio RM, et al. Dupilumab in chronic sinusitis with nasal polyposis, with and without asthma. Allergy Eur J Allergy Clin Immunol. 2015;70:107. https:\/\/doi.org\/10.1111\/all.12715.","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"1192_CR24","doi-asserted-by":"publisher","first-page":"S278","DOI":"10.1055\/s-0041-1728626","volume":"100","author":"R Boscke","year":"2021","unstructured":"Boscke R, Bruchhage KL. Real-life data on the effectiveness and safety of dupilumab in adult patients with uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Laryngo- Rhino- Otol. 2021;100:S278\u20139. https:\/\/doi.org\/10.1055\/s-0041-1728626.","journal-title":"Laryngo- Rhino- Otol"},{"key":"1192_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/all.15616","volume":"78","author":"F Cipolla","year":"2023","unstructured":"Cipolla F, La Mantia I. Chronic rinosinusitis with nasal polyps and dupilumab: results after six months of treatment. Allergy Eur J Allergy Clin Immunol. 2023;78:421\u20132. https:\/\/doi.org\/10.1111\/all.15616.","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"1192_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/all.15616","volume":"78","author":"L De Prado Gomez","year":"2023","unstructured":"De Prado Gomez L, Khan AH, Peters A, et al. EValuating trEatment RESponses of dupilumab versus omalizumab in type 2 patients: the EVEREST trial. Allergy Eur J Allergy Clin Immunol. 2023;78:616\u20137. https:\/\/doi.org\/10.1111\/all.15616.","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"1192_CR27","doi-asserted-by":"publisher","first-page":"S329","DOI":"10.1055\/s-0042-1747025","volume":"101","author":"SK Dennis","year":"2022","unstructured":"Dennis SK, Martin L, Marc D, et al. CRSwNP and dupilumab-experiences after one year of clinical use at a university ENT clinic. Laryngo- Rhino- Otol. 2022;101:S329. https:\/\/doi.org\/10.1055\/s-0042-1747025.","journal-title":"Laryngo- Rhino- Otol"},{"key":"1192_CR28","doi-asserted-by":"publisher","first-page":"S332","DOI":"10.1055\/s-0042-1747000","volume":"101","author":"H Mathias","year":"2022","unstructured":"Mathias H, Robert B, Marius T, et al. Dupilumab-treatment for uncontrolled CRSwNP: real-life 15-months follow-up data. Laryngo- Rhino- Otol. 2022;101:S332. https:\/\/doi.org\/10.1055\/s-0042-1747000.","journal-title":"Laryngo- Rhino- Otol"},{"key":"1192_CR29","doi-asserted-by":"publisher","first-page":"AB218","DOI":"10.1016\/j.jaci.2022.12.680","volume":"151","author":"I Schmale","year":"2023","unstructured":"Schmale I, Poulakis A, Abend A, et al. Real-world outcomes of dupilumab therapy for nasal polyposis in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2023;151:AB218. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.680.","journal-title":"J Allergy Clin Immunol"},{"key":"1192_CR30","doi-asserted-by":"publisher","first-page":"S284","DOI":"10.1055\/s-0041-1728858","volume":"100","author":"AS Hoffmann","year":"2021","unstructured":"Hoffmann AS, Eden J, Jansen F, et al. Efficacy of dupilumab (Dupixent) in the treatment of chronic rhinosinusitis with nasal polyps: first results from Hamburg. Laryngo- Rhino- Otol. 2021;100:S284\u20135. https:\/\/doi.org\/10.1055\/s-0041-1728858.","journal-title":"Laryngo- Rhino- Otol"},{"key":"1192_CR31","doi-asserted-by":"publisher","first-page":"S328","DOI":"10.1055\/s-0042-1747020","volume":"101","author":"HA Sophie","year":"2022","unstructured":"Sophie HA, Florian J, Benjamin B, et al. Real world data on the effectiveness and safety of dupilumab in adult patients with uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP). Laryngo- Rhino- Otol. 2022;101:S328. https:\/\/doi.org\/10.1055\/s-0042-1747020.","journal-title":"Laryngo- Rhino- Otol"},{"key":"1192_CR32","doi-asserted-by":"publisher","first-page":"AB214","DOI":"10.1016\/j.jaci.2023.11.691","volume":"153","author":"MP Ferreira Gom","year":"2024","unstructured":"Ferreira Gom MP, Ferreira S, Gomes Rosa JP, et al. Chronic rhinosinusitis with nasal polyposis: Portuguese experience with dupilumab in two centers. J Allergy Clin Immunol. 2024;153:AB214. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.691.","journal-title":"J Allergy Clin Immunol"},{"key":"1192_CR33","doi-asserted-by":"publisher","first-page":"AB103","DOI":"10.1016\/j.jaci.2023.11.337","volume":"153","author":"C Juarez","year":"2024","unstructured":"Juarez C, Eusebio I, Viciana MG, et al. Dupilumab effectivity in chronic rhinosinusitis with nasal polyps and asthma in real-life conditions. J Allergy Clin Immunol. 2024;153:AB103. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.337.","journal-title":"J Allergy Clin Immunol"},{"key":"1192_CR34","doi-asserted-by":"publisher","first-page":"AB210","DOI":"10.1016\/j.jaci.2023.11.677","volume":"153","author":"M Lanz","year":"2024","unstructured":"Lanz M, Eisenlohr C, Chartrand E, Herrera L. Early clinical improvement of anosmia and sinus nitric oxide in CRSwNP subjects treated with Dupilumab. J Allergy Clin Immunol. 2024;153:AB210. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.677.","journal-title":"J Allergy Clin Immunol"},{"key":"1192_CR35","doi-asserted-by":"publisher","first-page":"AB100","DOI":"10.1016\/j.jaci.2023.11.329","volume":"153","author":"A Peters","year":"2024","unstructured":"Peters A, Han J, Goeckner B, et al. Efficacy of Biologics in patients with moderate-to-severe, uncontrolled asthma and nasal polyps. J Allergy Clin Immunol. 2024;153:AB100. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.329.","journal-title":"J Allergy Clin Immunol"},{"key":"1192_CR36","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","volume":"126","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Bachert C, Amin N, et al. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Ann Allergy Asthma Immunol. 2021;126:584\u2013e5921. https:\/\/doi.org\/10.1016\/j.anai.2021.01.012.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1192_CR37","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.jaip.2020.12.059","volume":"9","author":"M Boguniewicz","year":"2021","unstructured":"Boguniewicz M, Beck LA, Sher L, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021;9:1212\u2013e12236. https:\/\/doi.org\/10.1016\/j.jaip.2020.12.059.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1192_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/alr.23059","volume":"13","author":"A Miglani","year":"2023","unstructured":"Miglani A, Soler ZM, Smith TL, et al. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis. Int Forum Allergy Rhinol. 2023;13:116\u201328. https:\/\/doi.org\/10.1002\/alr.23059.","journal-title":"Int Forum Allergy Rhinol"},{"key":"1192_CR39","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/lary.29766","volume":"132","author":"AH Khan","year":"2022","unstructured":"Khan AH, Reaney M, Guillemin I, et al. Development of sinonasal outcome test (SNOT-22) domains in chronic Rhinosinusitis with nasal polyps. Laryngoscope. 2022;132:933\u201341. https:\/\/doi.org\/10.1002\/lary.29766.","journal-title":"Laryngoscope"},{"key":"1192_CR40","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.jaip.2022.05.013","volume":"10","author":"WW Busse","year":"2022","unstructured":"Busse WW, Wellman A, Diamant Z, et al. Impact of dupilumab on SNOT-22 sleep and function scores in CRSwNP. J Allergy Clin Immunol Pract. 2022;10:2479\u2013e24823. https:\/\/doi.org\/10.1016\/j.jaip.2022.05.013.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1192_CR41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jaci.2017.11.051","volume":"142","author":"SF Weinstein","year":"2018","unstructured":"Weinstein SF, Katial R, Jayawardena S, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018;142:171\u2013e1771. https:\/\/doi.org\/10.1016\/j.jaci.2017.11.051.","journal-title":"J Allergy Clin Immunol"},{"key":"1192_CR42","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/all.15067","volume":"77","author":"J Mullol","year":"2022","unstructured":"Mullol J, Laidlaw TM, Bachert C, et al. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials. Allergy. 2022;77:1231\u201344. https:\/\/doi.org\/10.1111\/all.15067.","journal-title":"Allergy"},{"key":"1192_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4193\/Rhin18.282","volume":"58","author":"C Bachert","year":"2020","unstructured":"Bachert C, Zinreich SJ, Hellings PW, et al. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology. 2020;58:10\u20137. https:\/\/doi.org\/10.4193\/Rhin18.282.","journal-title":"Rhinology"},{"key":"1192_CR44","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/JAA.S391896","volume":"16","author":"WW Busse","year":"2023","unstructured":"Busse WW, Pavord ID, Siddiqui S, et al. Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma irrespective of baseline asthma characteristics. J Asthma Allergy. 2023;16:411\u20139. https:\/\/doi.org\/10.2147\/JAA.S391896.","journal-title":"J Asthma Allergy"},{"key":"1192_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4193\/Rhin20.415","volume":"59","author":"M Desrosiers","year":"2021","unstructured":"Desrosiers M, Mannent LP, Amin N, et al. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. Rhinology. 2021;59:301\u201311. https:\/\/doi.org\/10.4193\/Rhin20.415.","journal-title":"Rhinology"},{"key":"1192_CR46","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2147\/JAA.S355391","volume":"15","author":"C Bachert","year":"2022","unstructured":"Bachert C, Khan AH, Hopkins C, et al. Rapid and Continuing improvements in nasal symptoms with dupilumab in patients with severe CRSwNP. J Asthma Allergy. 2022;15:557\u201363. https:\/\/doi.org\/10.2147\/JAA.S355391.","journal-title":"J Asthma Allergy"},{"key":"1192_CR47","doi-asserted-by":"publisher","first-page":"E1770","DOI":"10.1002\/lary.29230","volume":"131","author":"S Fujieda","year":"2021","unstructured":"Fujieda S, Matsune S, Takeno S, et al. The effect of dupilumab on intractable chronic rhinosinusitis with nasal polyps in Japan. Laryngoscope. 2021;131:E1770\u20131777. https:\/\/doi.org\/10.1002\/lary.29230.","journal-title":"Laryngoscope"},{"key":"1192_CR48","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4193\/Rhin22.220","volume":"61","author":"SE Lee","year":"2023","unstructured":"Lee SE, Amin N, Mannent LP, et al. The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP. Rhinology. 2023;61:531\u201340. https:\/\/doi.org\/10.4193\/Rhin22.220.","journal-title":"Rhinology"},{"key":"1192_CR49","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/alr.22780","volume":"11","author":"C Hopkins","year":"2021","unstructured":"Hopkins C, Wagenmann M, Bachert C, et al. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2021;11:1087\u2013101. https:\/\/doi.org\/10.1002\/alr.22780.","journal-title":"Int Forum Allergy Rhinol"},{"key":"1192_CR50","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaip.2021.09.037","volume":"10","author":"J Mullol","year":"2022","unstructured":"Mullol J, Bachert C, Amin N, et al. Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2022;10:1086\u2013e10955. https:\/\/doi.org\/10.1016\/j.jaip.2021.09.037.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1192_CR51","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jaip.2022.02.026","volume":"10","author":"GW Canonica","year":"2022","unstructured":"Canonica GW, Bourdin A, Peters AT, et al. Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases. J Allergy Clin Immunol Pract. 2022;10:1515\u201326. https:\/\/doi.org\/10.1016\/j.jaip.2022.02.026.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1192_CR52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/lary.29911","volume":"132","author":"C-C Chuang","year":"2022","unstructured":"Chuang C-C, Guillemin I, Bachert C, et al. Dupilumab in CRSwNP: responder analysis using clinically meaningful efficacy outcome thresholds. Laryngoscope. 2022;132:259\u201364. https:\/\/doi.org\/10.1002\/lary.29911.","journal-title":"Laryngoscope"},{"key":"1192_CR53","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2500\/aap.2023.44.230015","volume":"44","author":"AT Peters","year":"2023","unstructured":"Peters AT, Wagenmann M, Bernstein JA, et al. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis. Allergy Asthma Proc. 2023;44:265\u201374. https:\/\/doi.org\/10.2500\/aap.2023.44.230015.","journal-title":"Allergy Asthma Proc"},{"key":"1192_CR54","doi-asserted-by":"publisher","first-page":"e1433","DOI":"10.1002\/cti2.1433","volume":"12","author":"P Gevaert","year":"2023","unstructured":"Gevaert P, Lee SE, Settipane RA, et al. Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps. Clin Transl Immunol. 2023;12. https:\/\/doi.org\/10.1002\/cti2.1433.","journal-title":"Clin Transl Immunol"},{"key":"1192_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23249","author":"C Bachert","year":"2023","unstructured":"Bachert C, Khan AH, Lee SE, et al. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52. Int Forum Allergy Rhinol. 2023. https:\/\/doi.org\/10.1002\/alr.23249.","journal-title":"Int Forum Allergy Rhinol"},{"key":"1192_CR56","doi-asserted-by":"publisher","unstructured":"Hellings PW, Peters A, Chaker AM et al (2021) Rapid and sustained effects of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps: analysis of the sinus-24 and sinus-52 phase 3 trails. Am J Respir Crit Care Med 203. https:\/\/doi.org\/10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A1345","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A1345"},{"key":"1192_CR57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1183\/13993003.congress-2022.1711","volume":"60","author":"C Bachert","year":"2022","unstructured":"Bachert C, Khan A, Fokkens W, et al. Onset, maintenance, and durability of response with dupilumab in chronic rhinosinusitis with nasal polyps. Eur Respir J. 2022;60:60. https:\/\/doi.org\/10.1183\/13993003.congress-2022.1711.","journal-title":"Eur Respir J"},{"key":"1192_CR58","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.anai.2022.08.710","volume":"129","author":"C Bachert","year":"2022","unstructured":"Bachert C, Khan A, Lee S, et al. Dupilumab improves chronic rhinosinusitis with nasal polyps disease outcomes irrespective of type 2 signature definition. Ann Allergy Asthma Immunol. 2022;129:S72\u20133. https:\/\/doi.org\/10.1016\/j.anai.2022.08.710.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1192_CR59","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/cea.14044","volume":"51","author":"C Bachert","year":"2021","unstructured":"Bachert C, Peters AT, Heffler E, et al. A responder analysis to demonstrate dupilumab treatment effect across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). Clin Exp Allergy. 2021;51:1665\u20136. https:\/\/doi.org\/10.1111\/cea.14044.","journal-title":"Clin Exp Allergy"},{"key":"1192_CR60","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/j.anai.2021.08.158","volume":"127","author":"W Busse","year":"2021","unstructured":"Busse W, Pavord I, Siddiqui S, et al. Dupilumab improves crswnp\/asthma outcomes in patients with crswnp and comorbid asthma irrespective of asthma characteristics. Ann Allergy Asthma Immunol. 2021;127:S52\u20133. https:\/\/doi.org\/10.1016\/j.anai.2021.08.158.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1192_CR61","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","volume":"7","author":"TM Laidlaw","year":"2019","unstructured":"Laidlaw TM, Mullol J, Fan C, et al. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. J Allergy Clin Immunol Pract. 2019;7:2462\u2013e24651. https:\/\/doi.org\/10.1016\/j.jaip.2019.03.044.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1192_CR62","doi-asserted-by":"publisher","first-page":"AB144","DOI":"10.1016\/j.jaci.2021.12.486","volume":"149","author":"A Lane","year":"2022","unstructured":"Lane A, Mullol J, Hopkins C, et al. Dupilumab leads to reduction of anosmia in patients with severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2022;149:AB144. https:\/\/doi.org\/10.1016\/j.jaci.2021.12.486.","journal-title":"J Allergy Clin Immunol"},{"key":"1192_CR63","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A1340","volume":"203","author":"A Peters","year":"2021","unstructured":"Peters A, Wagenmann M, Bernstein JA, et al. Efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps and allergic rhinitis. Am J Respir Crit Care Med. 2021;203:203. https:\/\/doi.org\/10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A1340.","journal-title":"Am J Respir Crit Care Med."},{"key":"1192_CR64","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.anai.2022.08.709","volume":"129","author":"Z Soler","year":"2022","unstructured":"Soler Z, Lane A, Patel Z, et al. Association between smell loss, disease burden, and dupilumab efficacy in chronic rhinosinusitis with nasal polyps. Ann Allergy Asthma Immunol. 2022;129:S72. https:\/\/doi.org\/10.1016\/j.anai.2022.08.709.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1192_CR65","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/resp.13268","volume":"23","author":"P Hellings","year":"2018","unstructured":"Hellings P, Bachert C, Mullol J, et al. Dupilumab improves ACQ-5 items in CRSwNP patients with comorbid asthma. Respirology. 2018;23:153. https:\/\/doi.org\/10.1111\/resp.13268.","journal-title":"Respirology"},{"key":"1192_CR66","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/ohn.627","volume":"170","author":"C Hopkins","year":"2024","unstructured":"Hopkins C, Mullol J, Khan AH, et al. Impact of dupilumab on sinonasal symptoms and outcomes in severe chronic rhinosinusitis with nasal polyps. Otolaryngol Head Neck Surg. 2024;170:1173\u201382. https:\/\/doi.org\/10.1002\/ohn.627.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"1192_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23249","author":"C Bachert","year":"2023","unstructured":"Bachert C, Khan AH, Lee SE, et al. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52. Int Forum Allergy Rhinol. 2023. https:\/\/doi.org\/10.1002\/alr.23249.","journal-title":"Int Forum Allergy Rhinol"},{"key":"1192_CR68","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/1945892420961969","volume":"35","author":"SS Mustafa","year":"2021","unstructured":"Mustafa SS, Vadamalai K, Scott B, Ramsey A. Dupilumab as add-on therapy for chronic rhinosinusitis with nasal polyposis in aspirin exacerbated respiratory disease. Am J Rhinol Allergy. 2021;35:399\u2013407. https:\/\/doi.org\/10.1177\/1945892420961969.","journal-title":"Am J Rhinol Allergy"},{"key":"1192_CR69","doi-asserted-by":"publisher","first-page":"e15120","DOI":"10.1111\/dth.15120","volume":"34","author":"M Napolitano","year":"2021","unstructured":"Napolitano M, Maffei M, Patruno C, et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. Dermatol Ther. 2021;34. https:\/\/doi.org\/10.1111\/dth.15120.","journal-title":"Dermatol Ther"},{"key":"1192_CR70","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000526365","volume":"184","author":"A Lyly","year":"2023","unstructured":"Lyly A, Genberg E, Kauppi P, et al. Real-life experience of biologic treatment for asthma on chronic rhinosinusitis: a Finnish cohort. Int Arch Allergy Immunol. 2023;184:149\u201360. https:\/\/doi.org\/10.1159\/000526365.","journal-title":"Int Arch Allergy Immunol"},{"key":"1192_CR71","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1183\/13993003.congress-2022.3319","volume":"60","author":"S Nolasco","year":"2022","unstructured":"Nolasco S, Campisi R, Cipolla A, et al. Dupilumab effectiveness in patients with type 2-high severe asthma and chronic rhinosinusitis with nasal polyps. Eur Respir J. 2022;60. https:\/\/doi.org\/10.1183\/13993003.congress-2022.3319.","journal-title":"Eur Respir J."},{"key":"1192_CR72","doi-asserted-by":"publisher","first-page":"100746","DOI":"10.1016\/j.waojou.2023.100746","volume":"16","author":"U F\u00f6rster-Ruhrmann","year":"2023","unstructured":"F\u00f6rster-Ruhrmann U, Stergioudi D, Szczepek AJ, et al. A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics. World Allergy Organ J. 2023;16. https:\/\/doi.org\/10.1016\/j.waojou.2023.100746.","journal-title":"World Allergy Organ J"},{"key":"1192_CR73","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2147\/JAA.S328988","volume":"14","author":"C Pelaia","year":"2021","unstructured":"Pelaia C, Lombardo N, Busceti MT, et al. Short-term evaluation of dupilumab effects in patients with severe asthma and nasal polyposis. J Asthma Allergy. 2021;14:1165\u201372. https:\/\/doi.org\/10.2147\/JAA.S328988.","journal-title":"J Asthma Allergy"},{"key":"1192_CR74","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.anai.2022.11.006","volume":"130","author":"P Berger","year":"2023","unstructured":"Berger P, Menzies-Gow A, Peters AT, et al. Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps. Ann Allergy Asthma Immunol. 2023;130:215\u201324. https:\/\/doi.org\/10.1016\/j.anai.2022.11.006.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1192_CR75","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/biomedicines12020390","volume":"12","author":"M Caminati","year":"2024","unstructured":"Caminati M, Maule M, Benoni R, et al. Dupilumab efficacy on asthma functional, inflammatory, and patient-reported outcomes across different disease phenotypes and severity: a real-life perspective. Biomedicines. 2024;12. https:\/\/doi.org\/10.3390\/biomedicines12020390.","journal-title":"Biomedicines"},{"key":"1192_CR76","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/jpm13081241","volume":"13","author":"G Ottaviano","year":"2023","unstructured":"Ottaviano G, De Corso E, Saccardo T, et al. Effectiveness of dupilumab in the treatment of adult and older adult patients with severe, uncontrolled CRSwNP. JPM. 2023;13. https:\/\/doi.org\/10.3390\/jpm13081241.","journal-title":"JPM"},{"issue":"1526","key":"1192_CR77","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/jpm12091526","volume":"12","author":"G Ottaviano","year":"2022","unstructured":"Ottaviano G, Saccardo T, Roccuzzo G, et al. Effectiveness of dupilumab in the treatment of patients with uncontrolled severe CRSwNP: a real-life Observational Study in Na\u00efve and Post-surgical patients. JPM. 2022;12(1526). https:\/\/doi.org\/10.3390\/jpm12091526.","journal-title":"JPM."},{"key":"1192_CR78","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3390\/jpm12101734","volume":"12","author":"S Torretta","year":"2022","unstructured":"Torretta S, De Corso E, Nava N, et al. Proposal for a structured outpatient clinic for dupilumab treatment in chronic rhinosinusitis with nasal polyps in the first year of treatment. J Pers Med. 2022;12:1734. https:\/\/doi.org\/10.3390\/jpm12101734.","journal-title":"J Pers Med"},{"key":"1192_CR79","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3390\/ph16040630","volume":"16","author":"C Galletti","year":"2023","unstructured":"Galletti C, Barbieri MA, Ciodaro F, et al. Effectiveness and safety profile of dupilumab in chronic rhinosinusitis with nasal polyps: real-Life Data in Tertiary Care. Pharmaceuticals (Basel). 2023;16. https:\/\/doi.org\/10.3390\/ph16040630.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1192_CR80","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/all.15134","volume":"77","author":"RJL van der Lans","year":"2022","unstructured":"van der Lans RJL, Fokkens WJ, Adriaensen GFJPM, et al. Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. Allergy. 2022;77:670\u20134. https:\/\/doi.org\/10.1111\/all.15134.","journal-title":"Allergy"},{"key":"1192_CR81","doi-asserted-by":"publisher","first-page":"e2023227","DOI":"10.23750\/abm.v94i5.14745","volume":"94","author":"G Bellocchi","year":"2023","unstructured":"Bellocchi G, Loperfido A, Passali FM, et al. Biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: a bicentric experience. Acta Biomed. 2023;94:e2023227. https:\/\/doi.org\/10.23750\/abm.v94i5.14745.","journal-title":"Acta Biomed"},{"key":"1192_CR82","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12890-023-02556-8","volume":"23","author":"M Al-Ahmad","year":"2023","unstructured":"Al-Ahmad M, Ali A, Khalaf M, et al. Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference? BMC Pulm Med. 2023;23:266. https:\/\/doi.org\/10.1186\/s12890-023-02556-8.","journal-title":"BMC Pulm Med"},{"key":"1192_CR83","doi-asserted-by":"publisher","first-page":"1127576","DOI":"10.3389\/fimmu.2023.1127576","volume":"14","author":"Z Danisman","year":"2023","unstructured":"Danisman Z, Linxweiler M, K\u00fchn JP, et al. Differential nasal swab cytology represents a valuable tool for therapy monitoring but not prediction of therapy response in chronic rhinosinusitis with nasal polyps treated with dupilumab. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1127576.","journal-title":"Front Immunol"},{"key":"1192_CR84","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12948-022-00171-2","volume":"20","author":"E Nettis","year":"2022","unstructured":"Nettis E, Brussino L, Patella V, et al. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life. Clin Mol Allergy. 2022;20:6. https:\/\/doi.org\/10.1186\/s12948-022-00171-2.","journal-title":"Clin Mol Allergy"},{"key":"1192_CR85","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12890-022-02046-3","volume":"22","author":"S Minagawa","year":"2022","unstructured":"Minagawa S, Araya J, Watanabe N, et al. Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP. BMC Pulm Med. 2022;22:258. https:\/\/doi.org\/10.1186\/s12890-022-02046-3.","journal-title":"BMC Pulm Med"},{"key":"1192_CR86","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/alr.23246","volume":"14","author":"E Garvey","year":"2024","unstructured":"Garvey E, Naimi B, Duffy A, et al. Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP). Int Forum Allergy Rhinol. 2024;14:651\u20139. https:\/\/doi.org\/10.1002\/alr.23246.","journal-title":"Int Forum Allergy Rhinol"},{"key":"1192_CR87","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s00405-023-08336-8","volume":"281","author":"I Suzaki","year":"2024","unstructured":"Suzaki I, Maruyama Y, Kamimura S, et al. Residual nasal polyp tissue following dupilumab therapy is associated with periostin-associated fibrosis. Eur Arch Oto-Rhino-Laryngol. 2024;281:1807\u201317. https:\/\/doi.org\/10.1007\/s00405-023-08336-8.","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"1192_CR88","doi-asserted-by":"publisher","first-page":"435","DOI":"10.4193\/Rhin22.129","volume":"6","author":"BR Haxel","year":"2022","unstructured":"Haxel BR, Hummel T, Fruth K, et al. Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps. Rhin. 2022;6:435\u201343. https:\/\/doi.org\/10.4193\/Rhin22.129.","journal-title":"Rhin"},{"key":"1192_CR89","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/jpm13020234","volume":"13","author":"G Ottaviano","year":"2023","unstructured":"Ottaviano G, De Corso E, Cantone E, et al. Measuring nasal patency and the sense of Smell in CRSwNP patients treated with dupilumab. J Pers Med. 2023;13. https:\/\/doi.org\/10.3390\/jpm13020234.","journal-title":"J Pers Med"},{"key":"1192_CR90","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1016\/j.jaip.2023.07.038","volume":"11","author":"IL Schmale","year":"2023","unstructured":"Schmale IL, Poulakis A, Abend A, et al. Chronic rhinosinusitis with nasal polyposis treated with dupilumab: real-world use and outcomes. J Allergy Clin Immunol Pract. 2023;11:3203\u201310. https:\/\/doi.org\/10.1016\/j.jaip.2023.07.038.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1192_CR91","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.anai.2021.05.018","volume":"127","author":"S Nowsheen","year":"2021","unstructured":"Nowsheen S, Darveaux JI. Dupilumab in the treatment of nasal polyposis: a retrospective, real-world study. Ann Allergy Asthma Immunol. 2021;127:386\u20137. https:\/\/doi.org\/10.1016\/j.anai.2021.05.018.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1192_CR92","doi-asserted-by":"publisher","first-page":"104310","DOI":"10.1016\/j.amjoto.2024.104310","volume":"45","author":"G Riva","year":"2024","unstructured":"Riva G, Garetto M, Borgione M, et al. Dupilumab improves sleep quality in chronic rhinosinusitis with nasal polyps. Am J Otolaryngol. 2024;45. https:\/\/doi.org\/10.1016\/j.amjoto.2024.104310.","journal-title":"Am J Otolaryngol"},{"key":"1192_CR93","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/jpm14050468","volume":"14","author":"G Ottaviano","year":"2024","unstructured":"Ottaviano G, Roccuzzo G, Lora L, et al. The impact of dupilumab on work productivity and emotional health in CRSwNP: a multicentric study in Northeast Italy. J Pers Med. 2024;14. https:\/\/doi.org\/10.3390\/jpm14050468.","journal-title":"J Pers Med"},{"key":"1192_CR94","doi-asserted-by":"publisher","first-page":"103927","DOI":"10.1016\/j.amjoto.2023.103927","volume":"44","author":"G Pecorari","year":"2023","unstructured":"Pecorari G, Piazza F, Borgione M, et al. The role of intranasal corticosteroids in chronic rhinosinusitis with nasal polyposis treated with dupilumab. Am J Otolaryngol. 2023;44:103927. https:\/\/doi.org\/10.1016\/j.amjoto.2023.103927.","journal-title":"Am J Otolaryngol"},{"key":"1192_CR95","doi-asserted-by":"publisher","first-page":"1121237","DOI":"10.3389\/fimmu.2023.1121237","volume":"14","author":"C Pelaia","year":"2023","unstructured":"Pelaia C, Benfante A, Busceti MT, et al. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1121237.","journal-title":"Front Immunol"},{"key":"1192_CR96","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.3390\/jcm12134374","volume":"12","author":"K Gerstacker","year":"2023","unstructured":"Gerstacker K, Ketterer MC, Jakob TF, Hildenbrand T. Real life observational study of treatment success of monoclonal antibodies for refractory chronic rhinosinusitis with nasal polyps. J Clin Med. 2023;12. https:\/\/doi.org\/10.3390\/jcm12134374.","journal-title":"J Clin Med"},{"key":"1192_CR97","doi-asserted-by":"publisher","first-page":"320","DOI":"10.4193\/Rhin22.408","volume":"61","author":"FF Brkic","year":"2023","unstructured":"Brkic FF, Liu DT, Klimbacher R, et al. Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD. Rhinology. 2023;61:320\u20137. https:\/\/doi.org\/10.4193\/Rhin22.408.","journal-title":"Rhinology"},{"key":"1192_CR98","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/jcm12113671","volume":"12","author":"R Book","year":"2023","unstructured":"Book R, Eligal S, Tal Y, Eliashar R. Biological treatment for uncontrolled chronic rhinosinusitis with nasal polyps: preliminary real-world results from a tertiary medical center. J Clin Med. 2023;12:12. https:\/\/doi.org\/10.3390\/jcm12113671.","journal-title":"J Clin Med."},{"key":"1192_CR99","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/jcm11040926","volume":"11","author":"E De Corso","year":"2022","unstructured":"De Corso E, Montuori C, Settimi S, et al. Efficacy of biologics on refractory eosinophilic otitis media associated with bronchial asthma or severe uncontrolled CRSwNP. J Clin Med. 2022;11:11. https:\/\/doi.org\/10.3390\/jcm11040926.","journal-title":"J Clin Med."},{"key":"1192_CR100","doi-asserted-by":"publisher","first-page":"e12049","DOI":"10.1002\/clt2.12049","volume":"11","author":"C M\u00fcmmler","year":"2021","unstructured":"M\u00fcmmler C, D\u00fcnzelmann K, Kneidinger N, et al. Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP. Clin Transl Allergy. 2021;11. https:\/\/doi.org\/10.1002\/clt2.12049.","journal-title":"Clin Transl Allergy"},{"key":"1192_CR101","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/alr.22951","volume":"12","author":"H Dharmarajan","year":"2022","unstructured":"Dharmarajan H, Falade O, Lee SE, Wang EW. Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022;12:986\u201395. https:\/\/doi.org\/10.1002\/alr.22951.","journal-title":"Int Forum Allergy Rhinol"},{"key":"1192_CR102","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2147\/JAA.S363527","volume":"15","author":"C Hopkins","year":"2022","unstructured":"Hopkins C, Buchheit KM, Heffler E, et al. Improvement in health-related quality of life with dupilumab in patients with moderate-to-severe asthma with comorbid chronic rhinosinusitis with\/without nasal polyps: an analysis of the QUEST study. J Asthma Allergy. 2022;15:767\u201373. https:\/\/doi.org\/10.2147\/JAA.S363527.","journal-title":"J Asthma Allergy"},{"key":"1192_CR103","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1111\/all.15844","volume":"78","author":"FS Ryser","year":"2023","unstructured":"Ryser FS, Yalamanoglu A, Valaperti A, et al. Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis. Allergy. 2023;78:2712\u201323. https:\/\/doi.org\/10.1111\/all.15844.","journal-title":"Allergy"},{"key":"1192_CR104","doi-asserted-by":"publisher","first-page":"e27471","DOI":"10.1097\/MD.0000000000027471","volume":"100","author":"M Bertlich","year":"2021","unstructured":"Bertlich M, Ihler F, Bertlich I, et al. Management of chronic rhinosinusitis with nasal polyps in Samter triad by low-dose ASA desensitization or dupilumab. Med (Baltim). 2021;100. https:\/\/doi.org\/10.1097\/MD.0000000000027471.","journal-title":"Med (Baltim)"},{"key":"1192_CR105","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/alr.22774","volume":"11","author":"S Bajpai","year":"2021","unstructured":"Bajpai S, Marino MJ, Rank MA, et al. Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: a real-world study. Int Forum Allergy Rhinol. 2021;11:1152\u201361. https:\/\/doi.org\/10.1002\/alr.22774.","journal-title":"Int Forum Allergy Rhinol"},{"key":"1192_CR106","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/all.15532","volume":"78","author":"MB Soyka","year":"2023","unstructured":"Soyka MB, Ryser FS, Br\u00fchlmann C, et al. Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis. Allergy. 2023;78:1036\u201346. https:\/\/doi.org\/10.1111\/all.15532.","journal-title":"Allergy"},{"key":"1192_CR107","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1007\/s00405-024-08461-y","volume":"281","author":"C Rosso","year":"2024","unstructured":"Rosso C, De Corso E, Conti V, et al. Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP. Eur Arch Oto-Rhino-Laryngol. 2024;281:3017\u201323. https:\/\/doi.org\/10.1007\/s00405-024-08461-y.","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"1192_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.08.594","author":"S Ferri","year":"2023","unstructured":"Ferri S, Montagna C, Casini M, et al. Sleep quality burden in chronic rhinosinusitis with nasal polyps and its modulation by dupilumab. Ann Allergy Asthma Immunol S. 2023. https:\/\/doi.org\/10.1016\/j.anai.2023.08.594.","journal-title":"Ann Allergy Asthma Immunol S"},{"key":"1192_CR109","doi-asserted-by":"publisher","first-page":"46","DOI":"10.17116\/otorino20228804146","volume":"88","author":"NV Boiko","year":"2023","unstructured":"Boiko NV, Stagnieva IV, Lodochkina OE, Kurbatova NV. [Experience with dupilumab in the treatment of chronic rhinosinusitis with nasal polyps]. Vestn Otorinolaringol. 2023;88:46\u201353. https:\/\/doi.org\/10.17116\/otorino20228804146.","journal-title":"Vestn Otorinolaringol"},{"key":"1192_CR110","doi-asserted-by":"publisher","first-page":"51","DOI":"10.17116\/otorino20228802151","volume":"88","author":"RA Larin","year":"2023","unstructured":"Larin RA, Mokeeva PP, Grishin AS. [Experience of biological therapy in severe forms of chronic rhinosinusitis with nasal polyps in the conditions of regional healthcare]. Vestn Otorinolaringol. 2023;88:51\u20138. https:\/\/doi.org\/10.17116\/otorino20228802151.","journal-title":"Vestn Otorinolaringol"},{"key":"1192_CR111","first-page":"187","volume":"2023","author":"Z Knizek","year":"2023","unstructured":"Knizek Z. Efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps with comorbid allergic rhinitis. Alergie. 2023;2023:187\u201391.","journal-title":"Alergie"},{"key":"1192_CR112","doi-asserted-by":"publisher","DOI":"10.1007\/s00106-024-01487-y","author":"HM Appel","year":"2024","unstructured":"Appel HM, Lochbaum R, Hoffmann TK, Hahn J. Chronic rhinosinusitis with nasal polyps-extension of dupilumab treatment intervals. HNO. 2024. https:\/\/doi.org\/10.1007\/s00106-024-01487-y.","journal-title":"HNO"},{"key":"1192_CR113","doi-asserted-by":"publisher","DOI":"10.1007\/s00106-024-01433-y","author":"A-R Staufenberg","year":"2024","unstructured":"Staufenberg A-R, Frankenberger HK, F\u00f6rster-Ruhrmann U, et al. Biologic therapy in patients with severe NSAID-exacerbated respiratory disease and previous aspirin desensitization\u202f: results of a multicentric study. HNO. 2024. https:\/\/doi.org\/10.1007\/s00106-024-01433-y.","journal-title":"HNO"},{"key":"1192_CR114","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","volume":"34","author":"C Hopkins","year":"2009","unstructured":"Hopkins C, Gillett S, Slack R, et al. Psychometric validity of the 22-item sinonasal outcome test. Clin Otolaryngol. 2009;34:447\u201354. https:\/\/doi.org\/10.1111\/j.1749-4486.2009.01995.x.","journal-title":"Clin Otolaryngol"},{"key":"1192_CR115","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/all.15650","volume":"78","author":"P Gevaert","year":"2023","unstructured":"Gevaert P, De Craemer J, Bachert C, et al. European academy of allergy and clinical immunology position paper on endoscopic scoring of nasal polyposis. Allergy. 2023;78:912\u201322. https:\/\/doi.org\/10.1111\/all.15650.","journal-title":"Allergy"},{"key":"1192_CR116","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"key":"1192_CR117","doi-asserted-by":"publisher","first-page":"538","DOI":"10.14639\/0392-100X-N2156","volume":"42","author":"M Trimarchi","year":"2022","unstructured":"Trimarchi M, Vinciguerra A, Rampi A, et al. A prospective study on the efficacy of dupilumab in chronic rhinosinusitis with type 2 inflammation. Acta Otorhinolaryngol Ital. 2022;42:538\u201344. https:\/\/doi.org\/10.14639\/0392-100X-N2156.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"1192_CR118","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1111\/all.15772","volume":"78","author":"E De Corso","year":"2023","unstructured":"De Corso E, Pasquini E, Trimarchi M, et al. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase IV real-life study (DUPIREAL). Allergy. 2023;78:2669\u201383. https:\/\/doi.org\/10.1111\/all.15772.","journal-title":"Allergy"},{"key":"1192_CR119","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40463-023-00663-4","volume":"52","author":"NJ Campion","year":"2023","unstructured":"Campion NJ, Brugger J, Tu A, et al. The real life efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP. J Otolaryngol - Head Neck Surg. 2023;52:56. https:\/\/doi.org\/10.1186\/s40463-023-00663-4.","journal-title":"J Otolaryngol - Head Neck Surg"},{"key":"1192_CR120","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00405-023-08309-x","volume":"281","author":"P Orlando","year":"2024","unstructured":"Orlando P, Licci G, Kuitche D, et al. Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report. Eur Arch Otorhinolaryngol. 2024;281:1317\u201324. https:\/\/doi.org\/10.1007\/s00405-023-08309-x.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1192_CR121","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/jpm12081215","volume":"12","author":"E Cantone","year":"2022","unstructured":"Cantone E, De Corso E, Ricciardiello F, et al. Olfaction recovery following dupilumab is independent of nasal polyp reduction in CRSwNP. J Pers Med. 2022;12:12. https:\/\/doi.org\/10.3390\/jpm12081215.","journal-title":"J Pers Med."},{"key":"1192_CR122","doi-asserted-by":"publisher","first-page":"7324","DOI":"10.26355\/eurrev_202308_33304","volume":"27","author":"D Mocellin","year":"2023","unstructured":"Mocellin D, Ioppi A, Gaglio G, et al. Severe chronic rhinosinusitis treated with dupilumab, a real-life analysis of early effectiveness. Eur Rev Med Pharmacol Sci. 2023;27:7324\u201336. https:\/\/doi.org\/10.26355\/eurrev_202308_33304.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1192_CR123","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00405-022-07679-y","volume":"280","author":"F Jansen","year":"2023","unstructured":"Jansen F, Becker B, Eden JK, et al. Dupilumab (Dupixent) tends to be an effective therapy for uncontrolled severe chronic rhinosinusitis with nasal polyps: real data of a single-centered, retrospective single-arm longitudinal study from a university hospital in Germany. Eur Arch Oto-Rhino-Laryngol. 2023;280:1741\u201355. https:\/\/doi.org\/10.1007\/s00405-022-07679-y.","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"1192_CR124","doi-asserted-by":"publisher","first-page":"100780","DOI":"10.1016\/j.waojou.2023.100780","volume":"16","author":"T Albrecht","year":"2023","unstructured":"Albrecht T, Sailer MM, Capitani F, et al. Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy. World Allergy Organ J. 2023;16. https:\/\/doi.org\/10.1016\/j.waojou.2023.100780.","journal-title":"World Allergy Organ J"},{"key":"1192_CR125","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/jpm13091404","volume":"13","author":"GL Piazzetta","year":"2023","unstructured":"Piazzetta GL, Lobello N, Chiarella E, et al. Targeting IL-4 and IL-13 receptors on eosinophils in CRSwNP patients: the clinical efficacy of dupilumab. J Pers Med. 2023;13:13. https:\/\/doi.org\/10.3390\/jpm13091404.","journal-title":"J Pers Med."},{"key":"1192_CR126","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00405-023-08184-6","volume":"281","author":"I La Mantia","year":"2024","unstructured":"La Mantia I, Grigaliute E, Ragusa M, et al. Effectiveness and rapidity on olfatory fuction recovery in CRS patients treated with dupilumab: a real life prospective controlled study. Eur Arch Otorhinolaryngol. 2024;281:219\u201326. https:\/\/doi.org\/10.1007\/s00405-023-08184-6.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1192_CR127","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13223-023-00782-7","volume":"19","author":"E Grose","year":"2023","unstructured":"Grose E, Li AY, Lee JM. Clinical outcomes of dupilumab therapy in chronic rhinosinusitis with nasal polyps in a Canadian tertiary care rhinology practice. Allergy Asthma Clin Immunol. 2023;19:26. https:\/\/doi.org\/10.1186\/s13223-023-00782-7.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1192_CR128","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/all.15796","volume":"78","author":"RJL van der Lans","year":"2023","unstructured":"van der Lans RJL, Otten JJ, Adriaensen GFJPM, et al. Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months. Allergy. 2023;78:2684\u201397. https:\/\/doi.org\/10.1111\/all.15796.","journal-title":"Allergy"},{"key":"1192_CR129","doi-asserted-by":"publisher","DOI":"10.1002\/lary.30983","author":"M Alicandri-Ciufelli","year":"2023","unstructured":"Alicandri-Ciufelli M, Marchioni D, Pipolo C, et al. Influence of prior endoscopic sinus surgery extent on dupilumab effectiveness in CRSwNP patients. Laryngoscope. 2023. https:\/\/doi.org\/10.1002\/lary.30983.","journal-title":"Laryngoscope"},{"key":"1192_CR130","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40463-022-00570-0","volume":"51","author":"SJ Kilty","year":"2022","unstructured":"Kilty SJ, Lasso A. Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps. J Otolaryngol - Head Neck Surg. 2022;51:17. https:\/\/doi.org\/10.1186\/s40463-022-00570-0.","journal-title":"J Otolaryngol - Head Neck Surg"},{"key":"1192_CR131","doi-asserted-by":"publisher","first-page":"457","DOI":"10.18176\/jiaci.0851","volume":"33","author":"G Paoletti","year":"2023","unstructured":"Paoletti G, Casini M, Malvezzi L, et al. Very rapid improvement in extended nitric oxide parameters is associated with clinical and functional improvement in patients with chronic Rhinosinusitis with nasal polyps treated with Dupilumab. J Investig Allergol Clin Immunol. 2023;33:457\u201363. https:\/\/doi.org\/10.18176\/jiaci.0851.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1192_CR132","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1002\/lary.31238","volume":"134","author":"F Giombi","year":"2024","unstructured":"Giombi F, Pace GM, Nappi E, et al. Radiological versus clinical 1-year outcomes of dupilumab in refractory CRSwNP: a real-life study. Laryngoscope. 2024;134:2626\u201333. https:\/\/doi.org\/10.1002\/lary.31238.","journal-title":"Laryngoscope"},{"key":"1192_CR133","doi-asserted-by":"publisher","DOI":"10.1111\/coa.14172","author":"E De Corso","year":"2024","unstructured":"De Corso E, Porru DP, Corb\u00f2 M, et al. Comparative real-world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients. Clin Otolaryngol. 2024. https:\/\/doi.org\/10.1111\/coa.14172.","journal-title":"Clin Otolaryngol"},{"key":"1192_CR134","doi-asserted-by":"publisher","first-page":"104275","DOI":"10.1016\/j.amjoto.2024.104275","volume":"45","author":"M Gelardi","year":"2024","unstructured":"Gelardi M, Giancaspro R, Quaranta VN, et al. Dupilumab\u2019s impact on nasal citology: real life experience after 1 year of treatment. Am J Otolaryngol. 2024;45. https:\/\/doi.org\/10.1016\/j.amjoto.2024.104275.","journal-title":"Am J Otolaryngol"},{"key":"1192_CR135","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-024-08574-4","author":"SO Sarnoch","year":"2024","unstructured":"Sarnoch SO, Pepi\u0107 A, Schmitz L, et al. The value of biomarkers in the therapy of CRSwNP with biologicals-a long-term follow-up of dupilumab therapy. Eur Arch Otorhinolaryngol. 2024. https:\/\/doi.org\/10.1007\/s00405-024-08574-4.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1192_CR136","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1007\/s00405-024-08553-9","volume":"281","author":"A Gal","year":"2024","unstructured":"Gal A, Gravier-Dumonceau R, Penicaud M, et al. Efficacy of dupilumab in real-life settings: a STROBE study. 2024;281:4781\u20134788. https:\/\/doi.org\/10.1007\/s00405-024-08553-9.","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"1192_CR137","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40463-023-00660-7","volume":"52","author":"FF Brkic","year":"2023","unstructured":"Brkic FF, Liu DT, R\u00fccklinger I, et al. Platelet-to-lymphocyte ratio might predict the response to dupilumab treatment for patients with nasal polyposis. J Otolaryngol Head Neck Surg. 2023;52:75. https:\/\/doi.org\/10.1186\/s40463-023-00660-7.","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"1192_CR138","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/alr.23340","volume":"14","author":"E Garvey","year":"2024","unstructured":"Garvey E, Naimi B, Duffy A, et al. Medication utilization for patients with chronic rhinosinusitis with nasal polyposis and asthma in 12 months pre- and post\u2010dupilumab initiation. Int Forum Allergy Rhinol. 2024;14:1399\u2013401. https:\/\/doi.org\/10.1002\/alr.23340.","journal-title":"Int Forum Allergy Rhinol"},{"key":"1192_CR139","doi-asserted-by":"publisher","first-page":"104106","DOI":"10.1016\/j.amjoto.2023.104106","volume":"45","author":"C Galletti","year":"2024","unstructured":"Galletti C, Ragusa M, Sireci F, et al. Dupilumab in chronic rhinosinusitis with nasal polyps: real life data in a multicentric sicilian experience. Am J Otolaryngol Head Neck Med Surg. 2024;45:104106. https:\/\/doi.org\/10.1016\/j.amjoto.2023.104106.","journal-title":"Am J Otolaryngol Head Neck Med Surg"},{"key":"1192_CR140","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/19458924231204128","volume":"38","author":"Y Tsunemi","year":"2024","unstructured":"Tsunemi Y, Nakayama T, Kashiwagi T, et al. Long-term efficacy of dupilumab for eosinophilic chronic rhinosinusitis. Am J Rhinol Allergy. 2024;38:14\u201322. https:\/\/doi.org\/10.1177\/19458924231204128.","journal-title":"Am J Rhinol Allergy"},{"key":"1192_CR141","doi-asserted-by":"publisher","first-page":"AB433","DOI":"10.1016\/j.jaci.2018.12.980","volume":"143","author":"C Bachert","year":"2019","unstructured":"Bachert C, Desrosiers M, Mullol J, et al. A randomized phase 3 study, Sinus-52, evaluating the efficacy and safety of Dupilumab in patients with severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019;143:AB433. https:\/\/doi.org\/10.1016\/j.jaci.2018.12.980.","journal-title":"J Allergy Clin Immunol"},{"key":"1192_CR142","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1371\/journal.pctr.0010009","volume":"1","author":"PM Rothwell","year":"2006","unstructured":"Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLOS Clin Trial. 2006;1. https:\/\/doi.org\/10.1371\/journal.pctr.0010009.","journal-title":"PLOS Clin Trial"},{"key":"1192_CR143","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/lary.27852","volume":"129","author":"N Bhattacharyya","year":"2019","unstructured":"Bhattacharyya N, Villeneuve S, Joish VN, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope. 2019;129:1969\u201375. https:\/\/doi.org\/10.1002\/lary.27852.","journal-title":"Laryngoscope"},{"key":"1192_CR144","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/alr.23321","volume":"14","author":"DI Martin-Jimenez","year":"2024","unstructured":"Martin-Jimenez DI, Moreno-Luna R, Callejon-Leblic A, et al. Improved quality of life in patients with chronic rhinosinusitis with nasal polyps associated with expanded types of endoscopic sinus surgery: a 2-year retrospective study. Int Forum Allergy Rhinol. 2024;14:1119\u201322. https:\/\/doi.org\/10.1002\/alr.23321.","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-025-01192-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-025-01192-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-025-01192-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T06:58:26Z","timestamp":1738738706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-025-01192-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":144,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1192"],"URL":"https:\/\/doi.org\/10.1007\/s11882-025-01192-y","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"2 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This\u00a0article does not contain any studies with human participants performed by any.of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13"}}